ATEC

Analyst Note: ATEC (Alphatec Holdings, Inc.)

Date: 2026-06-13 Current Price: $8.81

1. Structural Readiness

• State: Context-only
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 5.3% (High)

2. Thesis Layer

This is a TACTICAL, setup-led name. As of 2026-06-13, there is no named secular thesis attached to this specific setup in the current context. The investment case must be judged strictly on the quality of the business fundamentals and the eventual formation of a technical setup, rather than a pre-existing macro narrative. We do not invent a thesis; we evaluate the company on its operational execution and the structural quality of its price action once a setup forms.

3. Business Overview

Alphatec Holdings, Inc. is a medical technology company headquartered in Carlsbad, California, focused on the design, development, and advancement of technology for the surgical treatment of spine disorders.

• Revenue Model: The company derives revenue primarily from the sale of spinal surgery implants (used in the treatment of spine disorders) and medical imaging equipment (specifically the EOS platform) used for surgical planning and post-operative assessment.
• Product Portfolio:
• Implants: Includes the Alpha InformatiX platform (e.g., SafeOp Neural InformatiX System), Sigma transforaminal lumbar interbody fusion systems, Squadron lateral retractors, OsseoScrew systems, and various anterior/cervical fixation options (e.g., Aspida, AMP, OCT, Trestle Luxe). Materials range from allograft and PEEK to porous and 3D-printed titanium.
• Imaging: The EOS imaging ecosystem, including the EOSedge installed base and EOS Insight software.
• Distribution: Products are marketed and sold through a network of independent sales agents and direct sales representatives.
• Financial Performance (Management Expectations & Historical Data):
• 2025 Full Year: Total revenue was $764.2 million, a 25% increase year-over-year. Surgical volume grew 22%, and average revenue per surgery expanded 4% (Source: E15, E16).
• 2026 Guidance (as of May 5, 2026): Management expects total revenue of approximately $882 million, representing 15% growth year-over-year. Adjusted EBITDA is expected to be approximately $134 million (Source: E1, E3).
• Growth Drivers: Surgical revenue was up 17% in the most recent quarter, driven by a 21% increase in cases and a 23% increase in surgeon participation. The EOSedge installed base grew 39% year-over-year, and EOS Insight accounts more than doubled (Source: E4, E5). Implant volumes at EOS Insight accounts are increasing meaningfully post go-live (Source: E6).
• Capital Structure: On May 1, 2026, the Company entered into a credit agreement with JP Morgan Chase Bank, securing a $175.0 million senior secured term loan and a $125.0 million senior secured revolving credit facility (Source: E13).

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Rationale: The company demonstrates a history of revenue compound annual growth rate (CAGR) of approximately 35% since its transformation in 2018. Management expectations for 2026 show continued double-digit revenue growth (15%) and stable profitability (EBITDA guidance maintained despite revenue adjustments). The business model shows strong unit economics with expanding surgeon user bases (up 23% in the latest quarter, 20% in 2025) and increasing adoption of high-value technology platforms (EOS Insight).
• Valuation Context: Forward consensus EPS is projected at $0.32 for FY1 and $0.58 for FY2 (Source: E31).
• Conviction Stack:
• Thesis Strength: Moderate (Tactical/Setup-led, no macro thesis).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm strong operational metrics, revenue growth, and margin stability.
• Structural Quality: Unknown/Neutral. The technical setup is currently undefined.
• Rerating Potential: Dependent on the confirmation of the technical setup. The fundamental strength supports a potential rerating, but the technical trigger is absent.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• A confirmed breakout above a defined resistance level (conservative entry).
• Continued execution of the 15% revenue growth and $134M EBITDA guidance in subsequent quarters.
• Further expansion of the EOS Insight installed base and implant volume growth.
• What Would Invalidate the Case:
• Significant miss on the 2026 revenue or EBITDA guidance.
• Deterioration in surgical case volumes or surgeon adoption rates.
• Gaps in Evidence:
• Specific Catalysts: While growth is evident, specific near-term catalysts (e.g., new product launches, specific regulatory approvals) beyond the general "innovation" narrative are not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: 1) Management guidance for 15% revenue growth and $134M EBITDA in 2026; 2) Strong historical CAGR of 35% and recent 25% revenue growth in 2025; 3) Surgeon user base and EOS Insight account growth accelerating. Expected path: Management expects continued revenue growth and profitability; the stock will likely remain in a consolidation or volatility phase until a technical pivot is established. Expected horizon: Indefinite until technical setup forms.